[Image courtesy of Bora Pharmaceuticals]
Bora Pharmaceuticals announced that its board approved the acquisition of Upsher-Smith Laboratories for up to $210 million.Minnesota-based Upsher-Smith features a diversified portfolio of 48 generic products. It has manufacturing facilities in Plymouth and Maple Grove, Minnesota. Taipei, Taiwan-based Bora called the company a reliable partner with solid manufacturing capabilities, a robust distribution network and established commercial relationships.
According to a news release, Upsher-Smith’s Minnesota facilities can commercialize a broad range of dosage forms. Those include oral solid, powders and liquid, plus packaging. Through the acquisition, Bora says it gains capacity to support its CDMO business and completes its capabilities in the U.S. market.
Upsher-Smith also offers significant opportunities for Bora’s commercial Rx business, called…